Lv2
130 积分 2025-02-21 加入
New Lungs for Lung Cancer—Perils and Promises
1个月前
已完结
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
1个月前
已完结
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
1个月前
已完结
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2个月前
已完结
NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines TM ) Non-Small Cell Lung Cancer
2个月前
已关闭
Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
2个月前
已完结
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
2个月前
已完结
MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum-Pemetrexed
3个月前
已完结
The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer
4个月前
已完结
Practical insights into additional strength biowaivers for oral solid dosage forms: current requirements by major regulatory agencies and path towards harmonization
4个月前
已完结
皖公网安备34019202002308
